Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Rimiducid |
Synonyms | |
Therapy Description |
Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Rimiducid | AP1903|AP-1903|AP 1903 | Rimiducid (AP1903) is a small molecule that selectively binds to mutant FKBP12 and induces dimerization and downstream signaling, which can be used to activate a safety switch in transplanted cells to potentially induce apoptosis and prevent graft-versus-host disease (PMID: 9724721, PMID: 22047558, PMID: 28697888). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04249947 | Phase I | P-PSMA-101 CAR-T cells Rimiducid | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Active, not recruiting | USA | 0 |
NCT02065869 | Phase Ib/II | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant | Terminated | ITA | GBR | 0 |
NCT03958656 | Phase I | Anti-SLAMF7 CAR T cells + Cyclophosphamide + Fludarabine Rimiducid | T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma | Completed | USA | 0 |
NCT01744223 | Phase Ib/II | Rimiducid Rivogenlecleucel | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT02743611 | Phase I | Rimiducid BPX-701 | Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms | Terminated | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02792114 | Phase I | Rimiducid Mesothelin CAR-T cells Cyclophosphamide | T-Cell Therapy for Advanced Breast Cancer | Active, not recruiting | USA | 0 |
NCT02786485 | Phase I | Rimiducid Rivogenlecleucel | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT | Withdrawn | 0 | |
NCT03696784 | Phase I | Rimiducid Bendamustine + Fludarabine + iC9-CAR.19-IL15-Transduced CB-NK | Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | Recruiting | USA | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03741127 | Phase I | Rimiducid | Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101 | Active, not recruiting | USA | 0 |
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |